Design and synthesis of novel phe-phe hydroxyethylene derivatives as potential coronavirus main protease inhibitors
In response to the current pandemic caused by the novel SARS-CoV-2, we design new compounds based on Lopinavir structure as an FDA-approved antiviral agent which is currently under more evaluation in clinical trials for COVID-19 patients. This is the first example of the preparation of Lopinavir isosteres from the main core of Lopinavir conducted to various heterocyclic fragments. It is proposed that main protease inhibitors play an important role in the cycle life of coronavirus. Thus, the protease inhibition effect of synthesized compounds was studied by molecular docking method. All of these 10 molecules, showing a good docking score compared. Molecular dynamics (MD) simulations also confirmed the stability of the best-designed compound in Mpro active site.Communicated by Ramaswamy H. Sarma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Journal of biomolecular structure & dynamics - 40(2022), 17 vom: 30. Okt., Seite 7940-7948 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khorsandi, Zahra [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.09.2022 Date Revised 31.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/07391102.2021.1905549 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323406785 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323406785 | ||
| 003 | DE-627 | ||
| 005 | 20240331233143.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/07391102.2021.1905549 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1358.xml |
| 035 | |a (DE-627)NLM323406785 | ||
| 035 | |a (NLM)33784944 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khorsandi, Zahra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Design and synthesis of novel phe-phe hydroxyethylene derivatives as potential coronavirus main protease inhibitors |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2022 | ||
| 500 | |a Date Revised 31.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In response to the current pandemic caused by the novel SARS-CoV-2, we design new compounds based on Lopinavir structure as an FDA-approved antiviral agent which is currently under more evaluation in clinical trials for COVID-19 patients. This is the first example of the preparation of Lopinavir isosteres from the main core of Lopinavir conducted to various heterocyclic fragments. It is proposed that main protease inhibitors play an important role in the cycle life of coronavirus. Thus, the protease inhibition effect of synthesized compounds was studied by molecular docking method. All of these 10 molecules, showing a good docking score compared. Molecular dynamics (MD) simulations also confirmed the stability of the best-designed compound in Mpro active site.Communicated by Ramaswamy H. Sarma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a lopinavir | |
| 650 | 4 | |a molecular docking | |
| 650 | 4 | |a molecular dynamic simulation | |
| 650 | 4 | |a synthesis | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Coronavirus Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Dipeptides |2 NLM | |
| 650 | 7 | |a Ethylenes |2 NLM | |
| 650 | 7 | |a Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a phenylalanylphenylalanine |2 NLM | |
| 650 | 7 | |a 2577-40-4 |2 NLM | |
| 650 | 7 | |a hydroxyethylene |2 NLM | |
| 650 | 7 | |a 557-75-5 |2 NLM | |
| 650 | 7 | |a Cysteine Endopeptidases |2 NLM | |
| 650 | 7 | |a EC 3.4.22.- |2 NLM | |
| 650 | 7 | |a Coronavirus 3C Proteases |2 NLM | |
| 650 | 7 | |a EC 3.4.22.28 |2 NLM | |
| 700 | 1 | |a Afshinpour, Maral |e verfasserin |4 aut | |
| 700 | 1 | |a Molaei, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Askandar, Rafee Habib |e verfasserin |4 aut | |
| 700 | 1 | |a Keshavarzipour, Fariba |e verfasserin |4 aut | |
| 700 | 1 | |a Abbasi, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghi-Aliabadi, Hojjat |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of biomolecular structure & dynamics |d 1985 |g 40(2022), 17 vom: 30. Okt., Seite 7940-7948 |w (DE-627)NLM012639974 |x 1538-0254 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:17 |g day:30 |g month:10 |g pages:7940-7948 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/07391102.2021.1905549 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2022 |e 17 |b 30 |c 10 |h 7940-7948 | ||